本次网上业绩说明会将采用网络文字互动的方式举行，投资者可于 2024 年 4 月 15 日（星期一）15:00-17:00 通过网址 https://eseb.cn/1dgh23Tw93i 或使用微 信扫描下方小程序码即可进入参与互动交流。 二、 会议出席人员 证券代码：002294 证券简称：信立泰 编号：2024-017 深圳信立泰药业股份有限公司 关于举行 2023 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）《2023 年年度报告》、《2023 年年度报告摘要》已于 2024 年 3 月 26 日披露。 为便于广大投资者进一步了解公司 2023 年度经营情况，公司将于 2024 年 4 月 15 日（星期一）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 2023 年年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、 参会方式 深圳信立泰药业股份有限公司 董事会 二〇二四年四月二日 出席本次说明会的人员有：董事、总经理颜杰先生， ...

2024年4月1日 公司研究 期待恩那罗商业化放量，即将进入产品收获期 ——信立泰（002294.SZ）2023 年年报点评 要点 买入（维持） 当 前价：29.11元 事件：公司发布2023年年报，实现营业收入33.65亿元，同比-3.35%；归母净 利润5.80亿元，同比-8.95%；扣非归母净利润5.26亿元，同比-4.73%；经营 性净现金流8.39亿元，同比-13.53%；EPS（基本）0.52元。业绩低于市场预 作者 期。 分析师：张瀚予 点评： 执业证书编号：S0930523070010 021-52523861 2023年年底恩那罗®纳入医保，期待商业化放量。 创新药恩那罗®（药品通用 zhanghanyu@ebscn.com 名：恩那度司他片），主要用于非透析的成人慢性肾脏病患者的贫血治疗，2023 年通过谈判首次纳入国家医保目录，为国家医保乙类药品。该药是国内上市的新 市场数据 一代缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHI）药物。具有达标率高、升速 总股本(亿股) 11.15 超标率低、血栓风险小等特点。此外，还具有一天一次口服给药、用药依从性好， 总市值(亿元)： 324.52 一 ...

2024年03月28日 公司研究●证券研究报告 信立泰（ ） 公司快报 002294.SZ 医药 | 化学制剂Ⅲ 创新营收贡献增强，降压管线进入密集收获期 买入-A(维持) 投资评级 股价(2024-03-28) 28.87元 投资要点 全年业绩略有承压，Q4营收环比逐步向好。公司发布2023年年报：（1）2023 交易数据 年，公司实现营收33.65亿元（-3.35%，同增，下同），归母净利润5.80亿元 总市值（百万元） 32,184.75 （-8.95%），扣非归母净利润5.26亿元（-4.73%）。公司全年业绩略有下滑，主 流通市值（百万元） 32,177.51 要受泰嘉续标降价及天津、福建等地丢标影响。费用端看，公司销售费用、管理费 总股本（百万股） 1,114.82 用、研发费用分别为10.16亿元（-7.20%）、2.87亿元（+20.64%）、4.09亿元 流通股本（百万股） 1,114.57 （-23.34%），对应费用率分别为30.18%（-2.34pp）、8.52%（+1.46pp）、12.16% 12个月价格区间 37.53/25.93 （-3.70pp）。公司费用管控合理有效，管理 ...

[Table_Page] 年报点评|化学制药 证券研究报告 [信Table_立Title] 泰（002294.SZ） [公Tab司le_I评nves级t] 买入 当前价格 27.38元 短期业绩扰动，创新产品落地驱动新增长 合理价值 36.74元 前次评级 买入 [ 核Tabl 心e_Su 观mm 点ary] ： 报告日期 2024-03-27 ⚫ 公司发布2023年年度报告：公司2023年实现营收33.65亿元(-3.4%， [相Tab对le_P市icQ场uote表] 现 以下均按同比口径)，归母净利润5.80亿元(-9.0%)，扣非净利润5.26 亿元(-4.7%)，经营性现金流净额为8.39亿元(-13.5% )。公司单四季度 10% 2% 实现营收9.09亿元(-2.6%)，归母净利润1.01亿元(+3.5%)，扣非净利 -6%03/23 05/23 07/23 09/23 11/23 01/24 03/24 润1.01亿元(+18.5%)，经营性现金流净额为3.04亿元(+12.3%)。 -14% ⚫ 聚焦慢病领域，创新产品营收占比持续提升。分板块看：（1）公司2023 -22% 年制剂业务实现收入 ...

证券代码：002294 证券简称：信立泰 编号：2024-016 深圳信立泰药业股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2021]663 号文核准《关于核准深圳信 立泰药业股份有限公司非公开发行股票的批复》，深圳信立泰药业股份有限公司 （下称"公司"）向特定投资者发行人民币普通股 68,800,535 股，每股面值 1 元， 每股发行价人民币 28.37 元。募集资金共计人民币 195,187.12 万元，扣除不含税 发行费用人民币 1,980.55 万元，实际募集资金净额为人民币 193,206.57 万元。该 项募集资金已于 2021 年 5 月 24 日全部到位，并经大信会计师事务所（特殊普通 合伙）大信验字（2021）第 5-10001 号验资报告验证确认。 二、募集资金管理情况 为加强和规范募集资金的管理，提高资金的使用效率，维护全体股东的合法 利益，公司按照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所股票上市规则》《深 ...

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's revenue and profit performance in 2023 met expectations, with a commercial matrix for antihypertensive drugs about to form [1]. - The decline in revenue and net profit for 2023 was primarily due to price reductions from the renewal of Clopidogrel (Tigecycline) and unsuccessful bids in some regions, but the continued growth of Aliskiren under high medication adherence slightly lowered revenue and profit, which was in line with expectations [1]. - The company is expected to form a competitive advantage in the antihypertensive field with the anticipated launch of several products in 2024, including SAL0107, SAL0108, and S086 [1][2]. Financial Summary - In 2023, the company achieved operating revenue of 3.365 billion yuan, a year-on-year decrease of 3.35%, and a net profit attributable to shareholders of 580 million yuan, down 8.95% [1][3]. - The company’s R&D investment in 2023 was 1.047 billion yuan, accounting for 31.13% of revenue, indicating a strong commitment to innovation [1]. - The financial indicators show a decrease in sales expenses by 7.20% year-on-year, while management expenses increased by 20.64% [1][3]. Future Outlook - The company is projected to see net profits of 661 million yuan, 773 million yuan, and 938 million yuan for 2024, 2025, and 2026, respectively, with growth rates of 13.9%, 16.9%, and 21.4% [2][3]. - The report highlights that the company's innovation efforts are expected to become the main driver of performance, outlining a second growth curve for the company [2].

Innovation and Product Development - In 2023, the company achieved significant progress in innovation, with four new products in the上市审评阶段 and three in Phase III clinical trials[6] - The company’s new product revenue experienced rapid growth, contributing to an upward trend as the impact of generic drug pricing diminishes[6] - The company aims to become the leading provider of new hypertension drugs in China, with multiple products at various stages of development[6] - The company emphasizes the importance of innovation in improving health outcomes for hypertension patients, addressing a critical public health issue[6] - The innovative drug "Xinlitai" (generic name: Aliskiren) was renewed in the national medical insurance catalog, enhancing its market position as a unique domestic product[23] - The innovative drug "恩那罗®" was included in the national medical insurance catalog in December 2023, expected to provide new treatment options for chronic kidney disease patients[26] - The company submitted 7 IND applications and 2 new product registration applications in 2023, with 48 patents granted, including 43 invention patents[29] - The innovative biological drug JK07 has been approved to conduct Phase II clinical trials in the U.S., with plans to start patient enrollment in the first half of 2024[28] - The company is focusing on cardiovascular, renal, and metabolic disease areas, with a pipeline of competitive products expected to enhance profitability in the coming years[30] - The company is actively developing new drugs in cardiovascular, metabolic, and oncology fields, aiming to enhance its product pipeline and competitiveness[47] Financial Performance - The company's operating revenue for 2023 was CNY 3,365,343,342.73, a decrease of 3.35% compared to 2022[13] - Net profit attributable to shareholders for 2023 was CNY 580,066,240.84, down 8.95% from the previous year[13] - The net profit after deducting non-recurring gains and losses was CNY 525,862,387.30, a decrease of 4.73% year-on-year[13] - The net cash flow from operating activities was CNY 839,442,557.56, reflecting a decline of 13.53% compared to 2022[13] - Basic earnings per share for 2023 were CNY 0.520, down 10.34% from the previous year[13] - The total revenue for 2023 was approximately ¥3.37 billion, a decrease of 3.35% compared to ¥3.48 billion in 2022[36] - The pharmaceutical manufacturing segment generated ¥3.15 billion, accounting for 93.59% of total revenue, down 6.85% from ¥3.38 billion in 2022[37] - The company reported a net profit of 9,712.26 million RMB from its subsidiary Shandong Xinlitai Pharmaceutical Co., Ltd., contributing over 10% to the overall net profit[88] Research and Development - R&D investment reached CNY 1.047 billion, accounting for 31.13% of total revenue; sales expenses were CNY 1.016 billion, representing 30.18% of total revenue[25] - The company continues to focus on innovative drug development, particularly in cardiovascular and chronic disease treatment areas, aligning with national health strategies[21][22] - The company has established a research platform for high-end chemical drugs, innovative biological drugs, and medical devices, with numerous products in various stages of clinical development[96] - The number of R&D personnel increased to 784 in 2023, a rise of 3.84% from 755 in 2022[57] - The company is committed to advancing its research in both chemical and biological drugs, with a focus on addressing unmet medical needs in various therapeutic areas[48] Market Strategy and Expansion - The company plans to expand its market presence through new product launches and technological advancements in medical devices[47] - The company is focusing on building innovative technology platforms, including small nucleic acids, to address unmet clinical needs in chronic disease[32] - The company aims to accelerate the international launch of innovative products in the coming years[32] - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% increase in sales from this region within the next two years[145] - The company plans to enhance its R&D capabilities and accelerate the development of key products, focusing on innovative drug promotion and sales strategies[94] Governance and Compliance - The company has established a clear profit distribution policy, particularly regarding cash dividends, which is actively implemented[106] - The governance structure is continuously improved, ensuring clear responsibilities and coordination among various bodies[101] - The company has a robust internal control system in place, adhering to relevant laws and regulations[101] - The board of directors held 9 meetings during the reporting period, ensuring compliance and effective decision-making[107] - The company has implemented a rigorous quality management system, ensuring 100% compliance of marketed products[34] Shareholder and Investor Relations - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares, totaling 545,679,506.00 RMB, based on a total share capital of 1,091,359,012 shares after excluding repurchased shares[166] - The company has maintained a consistent cash dividend policy, distributing profits exceeding 30% of the average distributable profits over the past three years[165] - The company emphasizes sustainable development and shareholder rights, ensuring maximum benefits for shareholders[101] - The company actively engages with investors, particularly small and medium investors, to ensure reasonable returns while maintaining sustainable development[165] Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit in Shenzhen, Huizhou, and Dezhou, ensuring compliance with environmental regulations[195] - The company has implemented various environmental protection policies and standards, ensuring stable operation of waste treatment facilities[196] - The company has completed environmental impact assessments for its production facilities, receiving necessary approvals from local environmental authorities[199] - Shenzhen Xinlitai Pharmaceutical Co., Ltd. obtained the environmental protection acceptance certificate for its project in August 2010[200] Employee Engagement and Development - The company has implemented a multi-phase employee stock ownership plan, significantly incentivizing and retaining key employees[162] - The company emphasizes a differentiated compensation structure based on job importance, responsibility, and work difficulty, aiming to enhance employee income levels[162] - The company has a training plan that includes various training formats, such as online and offline training, to develop talent across different levels[163] - The total number of employees at the end of the reporting period was 3,517, with 2,378 in the parent company and 1,139 in major subsidiaries[160]

深圳信立泰药业股份有限公司 审 计 报 告 大信审字[2024]第 5-00024 号 深圳信立泰药业股份有限公司全体股东： 一、审计意见 大信审字[2024]第 5-00024 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 审计报告 我们审计了深圳信立泰药业股份有限公司（以下简称"贵公司"）的财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、 ...

证券代码：002294 证券简称：信立泰 编号：2024-012 一、投资情况概况 深圳信立泰药业股份有限公司 关于使用自有闲置资金投资理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：低风险及短期的金融机构（包括但不限于银行、信托、证券 公司等）理财产品。 2、投资金额：投资理财产品的金额在人民币 15 亿元以内，上述额度可由公 司及纳入公司合并报表范围内的子公司共同滚动使用，相关额度的使用期限不超 过 12 个月，期限内任一时点的交易金额不应超过委托理财额度。 3、特别风险提示：委托理财可能存在市场波动、政策风险、操作风险等风 险因素，投资收益具有不确定性。敬请广大投资者注意投资风险。 为提高自有资金使用效率，合理利用闲置资金，深圳信立泰药业股份有限公 司（下称"公司"）于 2024 年 3 月 24 日召开第六届董事会第二次会议，以 9 人 同意，0 人反对，0 人弃权，审议通过《关于使用自有闲置资金投资理财产品的 议案》，同意公司在满足正常经营和研发、生产、建设资金需求的情况下，根据 自有闲置资金状况和投资经 ...

华英证券有限责任公司 关于深圳信立泰药业股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 华英证券有限责任公司（以下简称"华英证券""保荐机构"）作为深圳信立 泰药业股份有限公司（以下简称"信立泰"或者"公司"）2020 年非公开发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规 定，对信立泰使用闲置募集资金进行现金管理的情况进行了审慎核查。核查的具 体情况及核查意见如下： 一、募集资金及投资项目基本情况 经中国证券监督管理委员会《关于核准深圳信立泰药业股份有限公司非公开 发行股票的批复》（证监许可〔2021〕663 号）核准，公司向特定投资者发行人民 币普通股 68,800,535 股，每股面值 1 元，每股发行价人民币 28.37 元。募集资金 共计人民币 195,187.12 万元，扣除不含税发行费用人民币 1,980.55 万元，实际募 集资金净额为人民币 193,206.57 万元。该项募集资金已于 202 ...